Meta-analysis of operation combined with Atorvastatin treatment for chronic subdural hematoma
GAN Yanling1 DENG Yu′er1 ZHANG Zhiqiang2 LI Cong2 ZHAN Wengang2 Tan Qijia2 XIE Caijun2
1.the Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510006, China;
2.the Second Department of Neurology, University Town Hospital of Guangdong Hospital of Traditional Chinese Medicine, Guangdong Province, Guangzhou 510120, China
Abstract:Objective To systematically evaluate the clinical effect of operation combined with Atorvastatin in the treatment of chronic subdural hematoma. Methods Wanfang, CNKI, CBM, PubMed, Embase and Web of Science databases were searched by computer and the retrieval period was from biuilding database to May 2019. Randomized controlled trials of operation combined with Atorvastatin in the treatment of chronic subdural hematoma were included. Meta-analysis was conducted on outcome indicators such as efficiency, incidence of complications and recurrence rate with RevMan 5.3 software. Results Finally, 16 literatures were included. The results of meta analysis showed that the effective rate of treatment group was higher than that of control group (OR = 5.74. 95%CI: 3.83, 8.62, P < 0.05), CSS scores in treatment group was lower than that in control group (MD = -4.37, 95%CI: -5.17, -3.57, P < 0.05), the incidence of infection in treatment group was lower than that of control group (OR = 0.22, 95%CI: 0.10, 0.46, P < 0.05), the incidence of intracranial emphysema in treatment group was lower than that in control group (OR = 0.19, 95%CI: 0.08, 0.45, P < 0.05), the incidence of brain injury in treatment group was lower than that in control group (OR = 0.12, 95%CI: 0.04, 0.36, P < 0.05) and the recurrence rate in treatment group was lower than that in control group (OR = 0.06, 95%CI: 0.03, 0.15, P < 0.05). There was no significant difference in the incidence of the increase of hematoma and the incidence of hepatic and renal dysfunction between treatment group and control group (P > 0.05). Conclusion Operation combined with Atorvastatin in the treatment of chronic subdural hematoma has a definite clinical effect. However, it needs to be verified by multi-center randomized clinical trials with high quality and large samples in the future.
[1] Ducruet AF,Grobelny BT,Zacharia BE,et al. The surgical management of chronic subdural hematoma [J]. Neurosurg Rev,2012,35(2):155-169.
[2] Chari A,Kolias AG,Santarius T,et al. Twist-drill craniostomy with hollow screws for evacuation of chronic subdural hematoma [J]. J Neurosurg,2014,121(1):176-183.
[3] Kutty SA,Johny M. Chronic subdural hematoma:a comparison of recurrence rates following burr-hole craniostomy with and without drains [J]. Turk Neurosurg,2014,24(4):494-497.
[4] Yan K,Gao H,Wang Q,et al. Endoscopic surgery to chronic subdural hematoma with neovessel septation:technical notes and literature review [J]. Neurol Res,2016,38(5):467-476.
[5] Wang D,Li T,Tian Y,et al. Effects of atorvastatin on chronic subdural hematoma:a preliminary report from three medical centers [J]. J Neurol Sci,2014,336(1/2):237-242.
[6] 陈孝平,汪建平.外科学[M].8版.北京:人民卫生出版社,2013:205-206.
[7] 孙传兴.临床疾病诊断依据治愈好转标准[M].北京:人民军医出版社,1998:91-93.
[8] 陈伯贤,吴晓纳.微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的临床观察[J].锦州医科大学学报,2019, 40(2):37-39.
[9] 黄晓斌.阿托伐他汀治疗慢性硬膜下血肿的效果观察[J].临床合理用药杂志,2018,11(34):67-69.
[10] 罗成焕,罗伟鹏,王沃.钻孔引流术联合阿托伐他汀治疗慢性硬膜下血肿疗效观察[J].海南医学,2019,30(5):591-593.
[11] 马一鸣.钻孔引流联合阿托伐他汀治疗慢性硬膜下血肿临床疗效观察[D].泸州:西南医科大学,2018.
[12] 马占峰,荔志云,田立桩,等.阿托伐他汀联合钻孔引流术治疗老年慢性硬膜下血肿的疗效观察[J].航空航天医学杂志,2017,28(2):167-169.
[13] 苗虎.微创穿刺手术联合阿托伐他汀治疗慢性硬膜下血肿的疗效分析[J].临床医药文献杂志,2017,4(21):4041-4042.
[14] 谈锦科.微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的疗效[J].现代诊断与治疗,2016,27(19):3653-3654.
[15] 王光辉.钻孔引流联合阿托伐他汀治疗慢性硬膜下肿56例临床效果分析[J].中西医结合心血管病电子杂志,2017,5(30):39-40.
[16] 伍学斌,康强,曾胜田,等.钻孔引流配合术后注入尿激酶联合阿托伐他汀治疗慢性硬膜下血肿的疗效观察[J].现代诊断与治疗,2018,29(14):2298-2300.
[17] 谢乐,刘锦平.慢性硬膜下血肿经微创穿刺+阿托伐他汀口服治疗的效果、预后及复发[J].辽宁医学杂志,2016,30(6):28-31.
[18] 谢宗新.微创穿刺联合阿托伐他汀治疗慢性硬膜下血肿的效果[J].河南医学高等专科学校学报,2018,30(6):576-578.
[19] 杨开华,余云湖,冉启山,等.阿托伐他汀钙片治疗非创伤性硬膜下血肿的临床研究[J].中国临床药理学杂志,2017,33(18):1751-1753.
[20] 杨云娜,张茜,顾征,等.阿托伐他汀辅助钻孔引流术治疗慢性硬膜下血肿患者的临床效果及对血清NSE的影响[J].中国生化药物杂志,2016,36(8):58-60.
[21] 詹发筝.微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的疗效分析[J].临床医药文献电子杂志,2018,5(A1):133-135.
[22] 张蕾,侯梅英,程刚,等.钻孔尿激酶注入联合阿托伐他汀钙对慢性硬膜下血肿患者术后神经功能及预后的临床观察[J].河北医药,2018,40(20):3137-3140.
[23] 周小利,卢二勤,查继辉,等.锥颅微创引流术联合阿托伐他汀治疗慢性硬膜下血肿临床分析[J].中国医学工程,2017,25(6):104-106.
[24] Soleman J,Nocera F,Mariani L. The conservative and pharmacological management of chronic subdural haematoma [J]. Swiss Med Wkly,2017,147:w14398.
[25] Jiang R,Zhao S,Wang R,et al. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients:A Randomized Clinical Trial [J]. JAMA Neurol,2018,75(11):1338-1346.
[26] Wang D,Li T,Wei H,et al. Atorvastatin enhances angiogenesis to reduce subdural hematoma in a rat model [J]. J Neurol Sci,2016,362:91-99.
[27] Li T,Wang D,Tian Y,et al. Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats [J]. J Neurol Sci,2014,341(1/2):88-96.
[28] Tang R,Shi J,Li X,et al. Effects of Atorvastatin on Surgical Treatments of Chronic Subdural Hematoma [J]. World Neurosurg,2018,117:e425-e429.